Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more
Evogene (EVGN) - Net Assets
Latest net assets as of September 2025: $20.09 Million USD
Based on the latest financial reports, Evogene (EVGN) has net assets worth $20.09 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.09 Million) and total liabilities ($6.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.09 Million |
| % of Total Assets | 77.01% |
| Annual Growth Rate | -8.65% |
| 5-Year Change | -73.91% |
| 10-Year Change | -85.7% |
| Growth Volatility | 49.56 |
Evogene - Net Assets Trend (2011–2024)
This chart illustrates how Evogene's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Evogene (2011–2024)
The table below shows the annual net assets of Evogene from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.84 Million | -48.27% |
| 2023-12-31 | $28.68 Million | -17.55% |
| 2022-12-31 | $34.79 Million | -45.14% |
| 2021-12-31 | $63.42 Million | +11.49% |
| 2020-12-31 | $56.88 Million | -5.54% |
| 2019-12-31 | $60.22 Million | +19.70% |
| 2018-12-31 | $50.31 Million | -27.49% |
| 2017-12-31 | $69.38 Million | -20.52% |
| 2016-12-31 | $87.29 Million | -15.87% |
| 2015-12-31 | $103.75 Million | -10.62% |
| 2014-12-31 | $116.08 Million | -6.95% |
| 2013-12-31 | $124.75 Million | +158.49% |
| 2012-12-31 | $48.26 Million | +0.35% |
| 2011-12-31 | $48.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evogene's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27407100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $363.00K | % |
| Other Comprehensive Income | $272.26 Million | % |
| Total Equity | $-1.45 Million | 100.00% |
Evogene Competitors by Market Cap
The table below lists competitors of Evogene ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sundance Strategies Inc
OTCQB:SUND
|
$7.32 Million |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
$7.32 Million |
|
Lambodhara Textiles Limited
NSE:LAMBODHARA
|
$7.32 Million |
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
$7.32 Million |
|
Alfa Energi Investama Tbk PT
JK:FIRE
|
$7.32 Million |
|
Heng Huat Resources Group Bhd
KLSE:0175
|
$7.31 Million |
|
MANAGEM
BC:MANAGEM
|
$7.31 Million |
|
Delek Automotive Systems Ltd
TA:DLEA
|
$7.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evogene's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,053,000 to -1,451,000, a change of -13,504,000 (-112.0%).
- Net loss of 16,485,000 reduced equity.
- New share issuances of 123,000 increased equity.
- Other comprehensive income increased equity by 2,904,000.
- Other factors decreased equity by 46,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.48 Million | -1136.11% |
| Share Issuances | $123.00K | +8.48% |
| Other Comprehensive Income | $2.90 Million | +200.14% |
| Other Changes | $-46.00K | -3.17% |
| Total Change | $- | -112.04% |
Book Value vs Market Value Analysis
This analysis compares Evogene's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $2.57 | $0.85 | x |
| 2012-12-31 | $2.62 | $0.85 | x |
| 2013-12-31 | $6.32 | $0.85 | x |
| 2014-12-31 | $4.63 | $0.85 | x |
| 2015-12-31 | $4.10 | $0.85 | x |
| 2016-12-31 | $3.43 | $0.85 | x |
| 2017-12-31 | $2.70 | $0.85 | x |
| 2018-12-31 | $1.94 | $0.85 | x |
| 2019-12-31 | $1.95 | $0.85 | x |
| 2020-12-31 | $1.26 | $0.85 | x |
| 2021-12-31 | $1.31 | $0.85 | x |
| 2022-12-31 | $6.78 | $0.85 | x |
| 2023-12-31 | $2.64 | $0.85 | x |
| 2024-12-31 | $-0.25 | $0.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evogene utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -193.69%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-40.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1.34% | 4.33% | 0.22x | 1.41x | $-4.16 Million |
| 2012 | -5.23% | -14.77% | 0.26x | 1.34x | $-7.35 Million |
| 2013 | -7.12% | -50.50% | 0.13x | 1.10x | $-21.35 Million |
| 2014 | -12.52% | -100.13% | 0.11x | 1.10x | $-26.14 Million |
| 2015 | -16.59% | -154.67% | 0.10x | 1.09x | $-27.59 Million |
| 2016 | -22.44% | -299.57% | 0.07x | 1.10x | $-28.32 Million |
| 2017 | -30.04% | -616.33% | 0.04x | 1.12x | $-27.78 Million |
| 2018 | -41.47% | -1188.21% | 0.03x | 1.17x | $-25.76 Million |
| 2019 | -36.12% | -2405.31% | 0.01x | 1.42x | $-23.13 Million |
| 2020 | -50.76% | -2247.50% | 0.01x | 1.56x | $-27.98 Million |
| 2021 | -51.80% | -2988.49% | 0.01x | 1.42x | $-33.16 Million |
| 2022 | -95.37% | -1590.33% | 0.03x | 2.01x | $-29.43 Million |
| 2023 | -198.12% | -423.39% | 0.11x | 4.24x | $-25.08 Million |
| 2024 | 0.00% | -193.69% | 0.21x | 0.00x | $-16.34 Million |
Industry Comparison
This section compares Evogene's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evogene (EVGN) | $20.09 Million | 1.34% | 0.30x | $7.32 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |